Moleculin announced the Investigational New Drug application for a Phase I trial of Moleculin’s drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the U.S. FDA.
Moleculin announced the Investigational New Drug application for a Phase I trial of Moleculin’s drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the U.S. FDA.